Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
ADAM8 signaling drives neutrophil migration and ARDS severity
Catharina Conrad, … , Mark R. Looney, Jörg W. Bartsch
Catharina Conrad, … , Mark R. Looney, Jörg W. Bartsch
Published February 8, 2022
Citation Information: JCI Insight. 2022;7(3):e149870. https://doi.org/10.1172/jci.insight.149870.
View: Text | PDF
Research Article Inflammation Pulmonology

ADAM8 signaling drives neutrophil migration and ARDS severity

  • Text
  • PDF
Abstract

Acute respiratory distress syndrome (ARDS) results in catastrophic lung failure and has an urgent, unmet need for improved early recognition and therapeutic development. Neutrophil influx is a hallmark of ARDS and is associated with the release of tissue-destructive immune effectors, such as matrix metalloproteinases (MMPs) and membrane-anchored metalloproteinase disintegrins (ADAMs). Here, we observed using intravital microscopy that Adam8–/– mice had impaired neutrophil transmigration. In mouse pneumonia models, both genetic deletion and pharmacologic inhibition of ADAM8 attenuated neutrophil infiltration and lung injury while improving bacterial containment. Unexpectedly, the alterations of neutrophil function were not attributable to impaired proteolysis but resulted from reduced intracellular interactions of ADAM8 with the actin-based motor molecule Myosin1f that suppressed neutrophil motility. In 2 ARDS cohorts, we analyzed lung fluid proteolytic signatures and identified that ADAM8 activity was positively correlated with disease severity. We propose that in acute inflammatory lung diseases such as pneumonia and ARDS, ADAM8 inhibition might allow fine-tuning of neutrophil responses for therapeutic gain.

Authors

Catharina Conrad, Daniela Yildiz, Simon J. Cleary, Andreas Margraf, Lena Cook, Uwe Schlomann, Barry Panaretou, Jessica L. Bowser, Harry Karmouty-Quintana, Jiwen Li, Nathaniel K. Berg, Samuel C. Martin, Ahmad Aljohmani, S. Farshid Moussavi-Harami, Kristin M. Wang, Jennifer J. Tian, Mélia Magnen, Colin Valet, Longhui Qiu, Jonathan P. Singer, Holger K. Eltzschig, CAPSys Study Group, Wilhelm Bertrams, Susanne Herold, Norbert Suttorp, Bernd Schmeck, Zachary T. Ball, Alexander Zarbock, Mark R. Looney, Jörg W. Bartsch

×

Figure 5

Schematic model of ADAM8–Myo1f interaction during neutrophil transmigration.

Options: View larger image (or click on image) Download as PowerPoint
Schematic model of ADAM8–Myo1f interaction during neutrophil transmigrat...
Neutrophil transmigration requires degradation of ECM and adhesion molecules, as well as cytoskeletal rearrangements. Active ADAM8 has been shown to process membrane proteins with immunological functions (red, ectodomain shedding) and cleave ECM components (blue, ECM degradation) previously (27, 33, 36). Our data suggest a potentially novel contribution of ADAM8 in modulating neutrophil motility by linking its cytoplasmic domain to the cytoskeletal motor protein Myo1f via SH3 domains (red box, cytoskeletal dynamics).

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts